Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

NICE updates guidance for arthritis treatments

August 26, 2010
Sales and Marketing NICE, Roche, rheumatoid arthritis

Five new drugs for rheumatoid arthritis have been given the thumbs up by NICE as second line treatment. Roche’s MabThera, …

News
Multaq

Multaq given limited approval from NICE

August 25, 2010
Medical Communications, Sales and Marketing Multaq, NICE, Sanofi-Aventis, atrial, dronedarone

NICE has given a restricted approval to Sanofi-Aventis’s Multaq as a second line treatment for atrial fibrillation patients. The guidance …

News

Avastin patient access scheme too complicated, says NICE

August 25, 2010
Sales and Marketing NICE, avastin, patient access

NICE is set to say no again to Avastin for use in patients with colorectal cancer. Avastin was first launched …

News

Pharma sector a ‘market for lemons’

August 20, 2010
Sales and Marketing NICE, health economics

  American sociologist Donald Light has made a provocative assessment of the pharma industry, saying the industry is able to exaggerate …

News

NICE decides Xolair is not value for money

August 12, 2010
Sales and Marketing NICE, Novartis, Xolair

NICE has refused to back the use of Novartis’ Xolair for young children, saying the asthma drug’s cost brings little …

News

NICE: the end of an era

August 9, 2010
Sales and Marketing Andrew Lansley, NICE, VBP, government

NICE is undergoing a momentus shift in its role which will see it leave behind the frequent clashes and controversy …

News

GPs urged to curb spending on prescriptions

August 6, 2010
GPs, NHS, NICE, NPC, prescriptions

GPs are being encouraged to reduce spending on prescriptions by following NICE’s cost-effectiveness guidelines. A new National Prescribing Centre (NPC) …

News

Generic clopidogrel helps NICE recommend blood clot prevention

August 5, 2010
Sales and Marketing NICE, Plavix

NICE has given preliminary approval for wider use of Sanofi-Aventis’s Plavix and Boehringer Ingelheim’s Persantine to prevent blood clots. It …

News

NICE set to recommend chronic constipation treatment

August 4, 2010
Sales and Marketing Movetis, NICE, Resolor

NICE has provisionally recommended Belgium-based Movetis’s Resolor as an option for the treatment of chronic constipation in women where laxatives …

News
Amgen's Prolia

NICE halts Prolia appraisal

August 2, 2010
Sales and Marketing Amgen, NICE, Prolia

NICE says it has been forced to terminate a review of Amgen’s bone density drug Prolia after the US biotech …

News
Iressa

NICE approves trio of cancer drugs

July 28, 2010
Sales and Marketing Iressa, MabThera, NICE, Xeloda

NICE has given its final recommendation to a trio of drugs for the treatment of various cancers, which means the …

News

NICE gets expanded role in quango cull

July 27, 2010
MHRA, NHS, NICE, government

The bonfire of the quangos has begun in earnest in the health sector, with 18 so-called “arm’s length bodies” cut …

News

New measures to help patients with mystery cancers

July 27, 2010
CUP, Cancer, NHS, NICE

Patients whose cancer has spread to other parts of the body from an unknown primary location are to be given …

News

NICE’s methods to be put under the spotlight

July 19, 2010
Sales and Marketing MRC, NICE, cost-effectiveness

The Medical Research Council has awarded £2.3 million for new research into the academic methods underpinning advice given by NICE …

News

NICE reaffirms positive opinion on Multaq

July 19, 2010
Sales and Marketing Multaq, NICE, antiarrhythmic, dronedarone

In its final draft guidance, UK cost-effectiveness body NICE has reaffirmed its previous positive opinion to recommend the limited use …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026